TCTMD’s Top 10 Most Popular Stories for December 2018
Concerns over late deaths with paclitaxel-coated balloons and stents led a diverse slate of drug and device news this month.
News from a meta-analysis showing a signal of late deaths with paclitaxel-coated balloons and stents, plus a story on how the findings quickly led to a pause in two trials, held the top slots on TCTMD’s most-read news for December 2018. Other articles in the top 10 this month include a fresh call for an RCT of Impella (Abiomed) in acute MI complicated by cardiogenic shock, the potential “resurrection” of device-based antihypertension therapies, and hints that thienopyridines could help identify migraine patients likely to benefit from closure of patent foramen ovale (PFO). Rounding out the list is a feature exploring how cardiology meetings have fared after MedTech Europe ended direct industry sponsorship of individual healthcare professionals.
A special meeting will be held in the coming months to review the issue. The lead author says he’s pleased endovascular specialists are taking it seriously.
A new meta-analysis points to a dramatic rise in mortality beyond 1 year. An outside expert urges sober reflection and better studies in this space.
Experts were not discouraged by the observational study, saying this is simply a reminder of the need for a large randomized trial—DanGer awaits.
The advisory panel, which chimed in on trial design and efficacy metrics, helped the FDA formulate development plans for a field that almost died.
While the guidelines don’t recommend a specific target for treatment, they do suggest additional therapy in high-risk patients with an LDL cholesterol level of 70 mg/dL or higher.
One expert believes that starting stabilized acute HF patients on the drug combo is simpler given they’re going to take it long-term.
Two studies demonstrate hypothesis-generating evidence that would support an upcoming randomized trial, experts say.
Definitive evidence is lacking regarding potential CV effects, but preliminary evidence suggests some reason for concern.
In diabetic patients with multivessel CAD, the SYNTAX score was not an independent predictor of hard clinical events in those receiving CABG.
In the wake of new regulations, a feared plunge in meeting attendance wasn’t seen and, in some cases, registration rose. But what’s next?